Delving into the Latest Updates on Rubicon Biotechnology LLC with Synapse

Overview

Tags

Neoplasms

Nervous System Diseases

Skin and Musculoskeletal Diseases

Fusion protein

Single-chain FV antibody fragment

Biological products

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Nervous System Diseases	1

Top 5 Drug Type	Count

Fusion protein	2
Single-chain FV antibody fragment	1
Biological products	1

Top 5 Target	Count

ANXA5(annexin A5)	1
HSP70 heat-shock proteins	1

A review.Due to a unique structure of tumors, TNT antibodies can bind with a great number of target cells in the hypoxic core of the injury zone.Long-standing laboratory and clin. research gave evidence for the utility of histone/DNA complexes as stable insoluble antigens available for binding with TNT antibodies in necrotic (but not in healthy!) cells.The ability of TNT antibodies to selectively accumulate in the necrotic cores of most solid tumors allows detection and killing of primary and metastatic tumors of any origin.

Rossiiskii Khimicheskii Zhurnal

Use of monoclonal antibodies for selective diagnostic and therapeutic targeting of human tumor lesions with a necrotic component

Author: Domogatskii, Sergei P. ; Parseghian, Missag H. ; Osidak, Mariya S. ; Mechetner, Eugene

This review discusses recent advances in in vivo diagnostics and therapeutic immunotargeting of necrotic lesions.The general principles of delivery of various effector mols. to tissues and organs using monoclonal antibodies are described.After reviewing antibody biodistribution and pharmacodynamics in human patients, the authors proceed to analyze these principles in specific exptl. models.The results of animal and clin. use of monoclonal antibodies against chromatin (histones and DNA) for in vivo detection of tumor necrotic zones are evaluated.In addition, the results of Phase I and II clin. trials based on the use of anti-chromatin monoclonal antibodies conjugated with radioactive isotopes to treat solid tumors (brain, colorectal, and other types of cancer) are described.Future directions for in vivo immunotargeting of solid tumors with necrotic components are discussed.

100 Deals associated with Rubicon Biotechnology LLC

Login to view more data

100 Translational Medicine associated with Rubicon Biotechnology LLC

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 20 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

2

Preclinical

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Fv-Hsp72 ( HSP70 heat-shock proteins )	Ischemic stroke More	Preclinical
AnxA5MOD-TNFa	Breast Cancer More	Preclinical
ARX-050 ( ANXA5 )	Neoplasms More	Discovery
RBB-002 ( HSP70 heat-shock proteins )	Toxicity More	Pending
RBB-003 ( HSP70 heat-shock proteins )	Toxicity More	Pending